Literature DB >> 19095365

Chronic prostatitis/chronic pelvic pain syndrome in males may be an autoimmune disease, potentially responsive to corticosteroid therapy.

I Tomaskovic1, B Ruzic, D Trnski, O Kraus.   

Abstract

UNLABELLED: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) represents the most common form of prostatitis. No known etiology factor in most cases can be found. It is possible that at least in some cases autoimmune response could be causative factor. Common treatment options include antibiotics, alpha blockers, myorelaxants, phytotherapeuticals, non steroidal anti-inflammatory drugs, hormonal treatment and surgery but corticosteroids have not been investigated. HYPOTHESIS: Chronic pelvic pain syndrome is in some cases autoimmune disease and this could have repercussions on treatment using low dose corticosteroids. RATIONALE: Currently corticosteroids are not a standard treatment option in CP/CPPS. Theoretical, experimental and scarce clinical evidence suggest that treatment with low dose corticosteroids could be beneficial in some patients with chronic prostatitis. If our hypothesis could be supported with well designed, randomized clinical trials this could change the approach of the medical treatment of CP/CPPS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19095365     DOI: 10.1016/j.mehy.2008.10.020

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  8 in total

Review 1.  Immune mediators of chronic pelvic pain syndrome.

Authors:  Stephen F Murphy; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Nat Rev Urol       Date:  2014-04-01       Impact factor: 14.432

Review 2.  New treatments for chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Adam C Strauss; Jordan D Dimitrakov
Journal:  Nat Rev Urol       Date:  2010-02-09       Impact factor: 14.432

3.  Histopathological classification criteria of rat model of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Xianjin Wang; Shan Zhong; Tianyuan Xu; Leilei Xia; Xiaohua Zhang; Zhaowei Zhu; Minguang Zhang; Zhoujun Shen
Journal:  Int Urol Nephrol       Date:  2014-11-20       Impact factor: 2.370

4.  T2 Peptide Represents a Major Autoantigen Epitope in Experimental Autoimmune Prostatitis.

Authors:  Yuqian Liu; Meng Tang; Qin Zhang; Cuican Li; Rundong Lv; Hanhui Min; Xiaohui Zhou
Journal:  Inflammation       Date:  2020-08-22       Impact factor: 4.092

Review 5.  Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy.

Authors:  Yuqian Liu; Junaid Wazir; Meng Tang; Rahat Ullah; Yueting Chen; Tingting Chen; Xiaohui Zhou
Journal:  Int Urol Nephrol       Date:  2020-11-16       Impact factor: 2.370

Review 6.  Chronic Prostatitis and Pelvic Pain Syndrome: Another Autoimmune Disease?

Authors:  Lei Chen; Meng Zhang; Chaozhao Liang
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-09-14       Impact factor: 4.291

7.  Investigation of Lymphocyte Subsets in Peripheral Blood of Patients with Benign Prostatic Hyperplasia.

Authors:  Ming Li; Da-Ming Xu; Shu-Bin Lin; Zheng-Liang Yang; Teng-Yu Xu; Jin-Huan Yang; Ze-Xin Lin; Ze-Kai Huang; Jun Yin
Journal:  Int J Gen Med       Date:  2021-10-20

8.  Gut Microflora Modulates Th17/Treg Cell Differentiation in Experimental Autoimmune Prostatitis via the Short-Chain Fatty Acid Propionate.

Authors:  He-Xi Du; Shao-Yu Yue; Di Niu; Chang Liu; Li-Gang Zhang; Jing Chen; Yang Chen; Yu Guan; Xiao-Liang Hua; Chun Li; Xian-Guo Chen; Li Zhang; Chao-Zhao Liang
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.